NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

Ilaris-醫藥品的洞察與市場預測:2030年

Ilaris- Drug Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 974758
出版日期 按訂單生產 內容資訊 英文 60 Pages
商品交期: 10個工作天內
價格
Ilaris-醫藥品的洞察與市場預測:2030年 Ilaris- Drug Insight and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 60 Pages
簡介

Canakinumab(以Ilaris品牌出售)是用於治療系統性幼年特發性關節炎和活動性Still病(包括成人發作的Still病)的藥物。它是針對白介素-1β的人單克隆抗體。

2020年6月,諾華ILARIS(canakinumab)獲得美國食品和藥物管理局(FDA)的批准,用於治療成人發作性靜止疾病(AOSD)1的新適應症。FDA批准了2歲及以上患者活動性Still病的適應症,包括全身性幼年特發性關節炎(SJIA)和AOSD。

未來幾年,由於全球對治療適應症的廣泛研究和不斷增加的醫療保健支出,Ilaris的市場前景將發生變化。這將擴大市場規模,使藥品製造商能夠更擴大滲透到市場中。

這些公司和學者正在努力評估挑戰並尋找可能影響Ilaris優勢的機會。正在開發的療法集中於治療/改善疾病狀況的新方法。

其他批准用於該疾病的產品正在給Ilaris帶來市場競爭,並且在不久的將來推出後期新興療法將極大地影響市場。

監管法規里程碑,開發活動以及一些關鍵發現的詳細說明提供了Ilaris當前的市場情況。

我們將通過對Ilaris從2017年到2030年銷售數據的深入分析來確定市場上Ilaris的整體情況,為客戶提供有關其治療產品組合的決策過程的支持。

本報告全面涵蓋7個主要市場上Ilaris臨床實驗藥。提供有關2020-2030年調查期間美國,歐洲5個國家(德國,法國,意大利,西班牙,英國)和日本7個主要市場的Ilaris的詳細概要。產品詳細內容中包含作用機制,劑量管理,合成途徑,法規的里程碑的研究開發活動,以及其他開發活動。再加上市場預測、 SWOT分析,市場上競爭趨勢,及其他新治療方法等未來市場趨勢。

目錄

第1章 產品概要

  • 表示
  • 作用機制
  • 投藥和管理
    • 劑型和濃度
  • 合成途徑
  • 藥理學
    • 藥效學
    • 藥物動力學
  • 副作用
  • 產品的概述
  • Ilaris的開發里程碑
  • 市售詳細內容
    • 美國
    • 歐洲
    • 日本
  • 專利詳細內容

第2章 SWOT分析

  • 分析師的見解

第3章 法規的里程碑

  • 核准
  • 研究開發
  • 臨床試驗資訊
  • 安全性和有效性
  • 產品開發活動

第4章 市場評估

  • 主要7個國家市場分析
  • 美國
  • 歐洲
  • 日本
  • 主要調查結果

第5章 市場競爭趨勢

第6章 新治療方法

第7章 附錄

  • 報告購買選擇
目錄
Product Code: DIDM0139

"Ilaris- Drug Insight and Market Forecast - 2030" report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Ilaris in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Drug Summary:

Canakinumab, sold under the brand name Ilaris is a medication for the treatment of systemic juvenile idiopathic arthritis and active Still's disease, including adult-onset Still's disease. It is a human monoclonal antibody targeted at interleukin-1 beta.

In June 2020, Novartis ILARIS (canakinumab) received US Food and Drug Administration (FDA) approval for a new indication to treat Adult-Onset Still's Disease (AOSD)1. The FDA granted an indication for active Still's disease including both systemic juvenile idiopathic arthritis (SJIA) and AOSD in patients aged 2 years and older.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug marketed details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around Ilaris.
  • The report contains historical and forecasted sales for Ilaris till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
  • The report also features the SWOT analysis with analyst insights and key findings of Ilaris.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Ilaris Analytical Perspective by DelveInsight

  • In-depth Ilaris Market Assessment

This report provides a detailed market assessment of Ilaris in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

  • Ilaris Clinical Assessment

The report provides the clinical trials information of Ilaris covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Ilaris is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Ilaris dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other approved products for the disease are giving market competition to Ilaris and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Ilaris.
  • Our in-depth analysis of the sales data of Ilaris from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Ilaris in the market.

Key Questions:

  • What is the prescribed dosage and strengths of Ilaris are available in the market?
  • What are the common adverse reactions or side effects of Ilaris?
  • What is the product type, route of administration and mechanism of action of Ilaris?
  • What are the chemical specifications of Ilaris?
  • How are the clinical trials diversified on the basis of the trial status?
  • What is the history of Ilaris, and what is its future?
  • What are the marketed details of Ilaris in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • How many patents have been granted to Ilaris and when these patents will get expire?
  • What are the pros (benefits) and cons (disadvantages) of Ilaris?
  • In which countries Ilaris got approval and when it gets launched?
  • What are the clinical trials are currently ongoing for Ilaris?
  • How the safety and efficacy results determined the approval of Ilaris?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Ilaris development?
  • What are the key designations that have been granted to Ilaris?
  • What is the historical and forecasted market scenario of Ilaris?
  • How is the market trend of Ilaris is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
  • What are the other approved products available and how these are giving competition to Ilaris?
  • Which are the late-stage emerging therapies under development for the treatment of the indicated condition?

Table of Contents

1. Product Overview

  • 1.1. Indication
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
    • 1.4.1 Dosage Forms and Strengths
  • 1.4. Route of Synthesis
  • 1.5. Pharmacology
    • 1.4.2 Pharmacodynamics
    • 1.4.3 Pharmacokinetics
  • 1.6. Adverse Reactions
  • 1.7. Product Snapshot
  • 1.8. Development Milestones of Ilaris
  • 1.9. Marketed Details
    • 1.4.4 United States
    • 1.4.5 Europe
    • 1.4.6 Japan
  • 1.10. Patent Details

2. SWOT Analysis

  • 2.1. Analyst Views

3. Regulatory Milestones

  • 3.1. Approvals
  • 3.2. Research and Development
  • 3.3. Clinical Trials Information
  • 3.4. Safety and Efficacy
  • 3.5. Product Developmental Activities

4. Market Assessment

  • 4.1. 7MM Market Analysis
  • 4.2. United States
  • 4.3. Europe
  • 4.4. Japan
  • 4.5. Key Findings

5. Market Competitors

6. Emerging Therapies

7. Appendix

  • 7.1. Report Purchase Options

List of Tables

  • Table 1 Ilaris, Description
  • Table 2 Ilaris, Trial Diversification
  • Table 3 Ilaris, Marketed Details United States
  • Table 4 Ilaris, Marketed Details Europe
  • Table 5 Ilaris, Marketed Details Japan
  • Table 6 Patent Details: Ilaris
  • Table 7 Ilaris, Clinical Trial Description, 2020
  • Table 8 Safety and Efficacy Results for Ilaris
  • Table 9 Ilaris, 7MM Market Size from 2017 to 2030 (in Million USD)
  • Table 10 Ilaris, US Market Size from 2017 to 2030 (in Million USD)
  • Table 11 Ilaris, EU Market Size from 2017 to 2030 (in Million USD)
  • Table 12 Ilaris, EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Table 13 Ilaris, Japan Market Size from 2017 to 2030 (in Million USD)
  • Table 14 Market Competitors
  • Table 15 Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of Ilaris
  • Figure 2 Patent Details, Ilaris
  • Figure 3 Ilaris, 7MM Market Size from 2017 to 2030 (in Million USD)
  • Figure 4 Ilaris, US Market Size from 2017 to 2030 (in Millions USD)
  • Figure 5 Ilaris, EU Market Size from 2017 to 2030 (in Millions USD)
  • Figure 6 Ilaris, EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Figure 7 Ilaris, Japan Market Size from 2017 to 2030 (in Millions USD)